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Background. Transplantation of untreated rat bone marrow into mouse recipients 
conditioned by total-body irradiation results in fully xenogeneic chimerism 
(rat - mouse). The chimerism is stable for up to 70 months, survival is excellent, and 
there is no evidence for graft-versus-host disease. We recently reported the long-term 
survival (> 780 days) of donor-specific pancreatic islet xenografts in these fully 
xenogeneic chimeras. 
Methods. Chimeras were prepared and typed for chimerism at 6 weeks, and diabetes 
was induced by streptozocin injection. Donor-specific pancreatic islets were placed 
under the renal capsule and recipient blood glucose levels were followed biweekly. The 
aim of this study was to examine whether the transplanted pancreatic islets exhibited 
normal function in a xenogeneic environment and assess whether the islet xenografts 
were not only sufficient to support euglycemia but also regulated in function in 
response to a glucose challenge. 
Results. We report for the first time that donor-specific rat islet xenografts were 
capable of producing normal basal and peak levels of insulin and responding to a 
glucose challenge in a manner similar to that of normal mouse islets. 
Conclusions. These data indicate that donor-specific rat islet xenografts are functional 
and regulated normally in fully xenogeneic (rat - mouse) chimeras. (SURGERY 
7992;772:327-32.) 
From the Department of Surgery, Division of Transplantation, University of Pittsburgh School 
of Medicine, Pittsburgh, Pa. 
I DIABETES IS A systemic autoimmune disease state 
results in destruction of the insulin-producing 
II-islets and other severe complications. It has been 
""'''''Ulil:iLII"i1U::U that the severity and incidence of diabe-
complications (microangiopathy, blind-
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ness, and renal failure) is influenced by the metabolic 
control of glucose homeostasis, in that hyperglycemia 
results in accelerated progression of the complications 
associated with diabetes. Attempts to achieve normo-
glycemia with exogenous insulin have been limited by 
hypoglycemia and patient noncompliance. It is now be-
lieved that transplantation of the insulin-producing 
P-cells as a whole pancreas, or as a free cellular graft, 
is the most physiologic approach to achieve complete 
glucose homeostasis. Cellular transplantation offers the 
following advantages: (1) the ease of the surgical 
approach, (2) ability for cryopreservation or in vitro 
manipulation with transplantation at a later date, and 
(3) avoidance of the requirement for anastomoses and 
exocrine drainage associated with whole-pancreatic 
graft placement. I-3 However, this approach has been 
limited by graft rejection that has not been controlled by 
SURGERY 327 
-
. ;-, 
----,-----
_.----
328 Ricordi et al. 
conventional immunosuppressive agents and a shortage 
of pancreases available for transplantation.4 Attempts to 
modify the immunogenicity of transplanted islets by a 
variety of approaches have achieved only limited suc-
cess. 5-12 The induction of donor-specific transplantation 
tolerance across a species barrier has been suggested as 
one approach to overcome both graft rejection and the 
shortage of donor organs. 
We recently developed a model to induce donor-spe-
cific transplantation tolerance through preparation of 
bone marrow chimeras (rat - mouse). Transplanta-
tion of untreated rat bone marrow stem cells into recip-
ient mice conditioned by total-body irradiation resulted 
in donor-specific transplantation tolerance in vivo and 
in vitro, excellent survival, and stable multilineage chi-
merism.13, 14 Donor-specific pancreatic islets were per-
manently accepted (>180 days) by the chimeric recip-
ients, whereas major histocompatibility complex 
(MHC)-disparate grafts were rejected rapidly.! j We 
have now examined whether regulation of function and 
maintenance of glucose homeostasis could be achieved in 
a xenogeneic environment. We report here that donor-
specific rat islet xenografts are functional and normally 
regulated in function in a xenogeneic mouse environ-
ment in fully xenogeneic (rat -+ mouse) chimeras. 
MATERIAL AND METHODS 
Animals. Six- to eight-week-old male C57BL/l OSnJ 
(BI0), BIO.BR/Sgn (BI0.BR) mice were purchased 
from the Jackson Laboratory (Bar Harbor, Maine). 
Four- to 8-week-old male Fisher 344 (F344; RtIAl) and 
Wistar-Furth (WF; RtIA U) male rats were purchased 
from Harlan Sprague Dawley Inc. (Indianapolis, Ind.). 
Fully xenogeneic reconstitution (WF rat - B10 
mouse). Fully xenogeneically reconstituted animals 
were prepared as described previously.!S After 28 days 
animals were typed to document chimerism by flow cy-
tometry with anti-class I rat and mouse monoclonal an-
tibody staining.!3 
Diabetes. Six weeks after fully xenogeneic bone 
marrow reconstitution, chimeras were made diabetic as 
described previously. I 5 
Rat islet isolation and transplantation. Rat islets 
were separated by collagenase digestion as described 
previously. IS, 16 
Intraperitoneal glucose tolerance test (IPGTT). 
IPGTTs were performed in the chimeras 8 months af-
ter the islet transplantation. The animals were fasted 
overnight and then injected intraperitoneally with 25% 
glucose (2 gm glucose/kg body weight).!7 Blood samples 
were obtained before and 15,30, and 60 minutes after 
glucose injection and analyzed for plasma glucose and 
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insulin levels. The K value, which represents the kinet. 
ics of return to normoglycemia after a glucose challenc:r, 
was calculated from the straight line describing 'e 
change in glucose over time according to the stana. d 
formula. 18 Statistics are presented as mean ± SEM and 
significance of different was assessed by the Student t 
test. 
Insulin assay. Insulin concentration in the serum was 
determined by a double-antibody radioimmunoassay 
with 12sI-labeled human insulin and a human insulin 
standard. 17 
RESULTS 
Characterization of fully xenogeneic chimeras 
(WF - B10 mouse or F344 rat -- B10 mouse). Fully 
xenogeneic chimeras (WF - B 10, n = 8) were r,e· 
pared and typed for engraftment 6 weeks after recor 
tution. A second group of chimeras was prepared v. ,Lh 
F344 rat bone marrow donors (n = 6). Diabetes was 
induced in the chimeras with streptozocin (Fig. 1). 
Daily blood glucose monitoring was performed. All 
mice had diabetes as evidenced by serum glucose levels 
greater than 300 mg/dl. Mice that remained hypergly-
cemic for greater than 7 days were transplanted with 
800 donor-specific islet xenografts placed under the re-
nal capsule. As in our past experience, survival of the 
donor-specific islet xenografts was prolonged signifi-
cantly (median survival time >8 months), whereas 
MHC-disparate third-party grafts were rejected rap-
idly (Fig. 2). 
Xenogeneic rat islets: Evidence for regulati01; ,f 
function. Plasma glucose levels normalized within 1 
week after subcapsular islet xenotransplantation. How-
ever, nonfasting plasma glucose levels do not provide an 
accurate assessment of regulation of glucose homeosta-
sis in recipients of islet transplants. For this reason, IP-
GTTs were performed in selected chimeras 8 months 
after graft placement (Table I). K values were calcu-
lated to determine the kinetics of return to normoglyce-
mia after glucose challenge. Fasting plasma glucose 
levels were determined in individual animals (n = 3) 
before and after intraperitoneal injection of 25% glucose 
(2 gm/kg body weight). No significant difference was 
observed in the fasting plasma glucose levels of chime· 
ras compared with normal controls. More importa:" 
comparable K values were present in the two group'. 
indicating normal regulation of islet function in a xeno-
geneic environment. 
Basal and peak insulin determinations were made in 
the chimeras during the IPGTTs (Table I). The 
chimeric recipients of xenogeneic rat islets demonstrated 
production of insulin levels similar to those for normal 
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Protocol for preparation of diabetic fully xenogeneic 
cru.mf"r". (rat - mouse). Recipients were typed for chimerism 
at 6 weeks and diabetes was then induced by streptozocin. 
Donor-specific or third-party pancreatic islet xenografts were 
under left renal subcapsular space. 
,ml:ltrlnl!l. Stimulated insulin release (peak insulin level 
per milliliter]) was higher in chimeras 
± 2.43 ng/ml) than in normal mice (4.21 ± 2.21 
However, this result was not statistically 
The assay for rat insulin is cross-reactive with that for 
mouse. To confirm that the insulin was produced by 
islet xenografts in the chimeras and not caused by 
of native pancreatic islet tissue, a trans-
nephrectomy was performed 1 day after the 
~q""D~I~ 
. Blood glucose determinations were made dail y. 
was a prompt return of hyperglycemia in all chi-
(n = 3), confirming that the transplanted islets 
in fact, the source of the insulin produced. 
. ~bvidence for insulin and glucagon production by 
pancreatic islet xenografts. The isolated islet is a 
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Fig. 2. Life-table survival of pancreatic islet xenografts in 
fully xenogeneic (rat - mouse) chimeras. Minimum fol-
low-up was 8 months. 
complex composed of acinar tissue including ,a-cells, 
glucagon-producing a-cells, a-cells, lymphoid cells, and 
antigen-presenting cells. We previously characterized 
the presence of insulin in the rat islet xenografts. 15 As 
a further assessment of graft viability and function, we 
analyzed the transplanted a-islets for evidence of gluca-
gon by immunohistochemical analyses. Glucagon was 
present in all islet xenografts examined (n = 6), dem-
onstrating that the a-cells can survive in a xenogeneic 
environment as well. As with the I)-cells, there was no 
evidence of chronic rejection. As in our past experience, 
all islet xenografts had histochemical evidence for the 
presence of insulin. The islets were well granulated and 
had no evidence for inflammatory cell infiltrates sug-
gestive of chronic rejection (Fig. 3). 
DISCUSSION 
Type I diabetes is a multifactorial disease that affects 
0.4% of white people in the United States. It is the sin-
gle most common cause of renal failure that requires 
transplantation. In excess of 50% of patients with type 
I diabetes have renal failure in their lifetime. It has be-
come clear that the underlying defect in type I diabetes 
is one of chronic systemic autoimmunity. Since the ad-
vent of insulin therapy, most acute deaths caused by in-
sulin deficiency have been prevented, but the complica-
tions associated with the disease have not been elimi-
nated. Glucose homeostasis is believed to exert a 
significant influence on the development and severity of 
the complications associated with diabetes. However, 
tight glucose homeostasis has been difficult to achieve, 
and patients are at constant risk for hypoglycemia 
caused by the pharmacologic administration of insulin. 
Even with tight glucose control, the majority of patients 
eventually have a constellation of progressive systemic 
complications, including renal failure, proliferative 
retinopathy leading to blindness, and peripheral neur-
opathy. Transplantation of the whole pancreas, or pu-
'.:i 
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Fig. 3. Representative immunoperoxidase stain to detect presence of glucagon in renal subcapsular pancreatic 
islet xenografts 8 months after transplantation (A). Note absence of inflammatory cell infiltrates. Comparison was 
made with normal mouse pancreas (8). 
Table I. Intraperitoneal glucose tolerance testing 
Group 
Rat - mouse chimera 
Normal 810 mouse 
Fasting plasma 
glucose (mg/dl) 
92 ± 10 
89 ± 12 
Values represent mean ± SO for three animals per group. 
rified insulin-producing J3-islets, is now believed to be 
the best approach to achieve complete glucose homeo-
stasis. However, transplantation of whole pancreas, or 
even the isolated J3-islets, which constitute at most 2% of 
the total pancreatic mass, has been limited by rejection 
and a shortage of organs available for transplantation. 
The induction of tolerance across a species barrier has 
been suggested as one potential approach to overcome 
both of these limitations. To date, the only true state of 
Kvalue Insulin level (ngjml) 
(%/min) Basal Peak 
2.5 ± 0.34 0.02 ± 0.02 5.81 ± 2.43 
2.3 ± 0.24 0.03 ± 0.02 4.21 ± 2.21 
donor-specific transplantation tolerance has been that 
associated with bone marrow chimerism. 19-24 The fir~l 
association between chimerism and tolerance was rt:-
ported by Billingham et al. 19 in 1953, in which they 
demonstrated the induction of permanent and stable 
systemic donor-specific transplantation tolerance by 
transplantation of allogeneic bone marrow stem cells 
into newborn mouse recipients. The induction of simi-
lar medawarian tolerance was subsequently achieved in 
~ 
-. 
recipients of bone marrow from genetically dif-
donors of the same species with a number of 
ve approaches.2o-24 We recently reported a 
for preparation of Fully xenogeneic chimeras 
- mouse) in which stable engraftment of rat donor 
marrow stem cells occurred in mouse recipients. 14 
exhibited systemic donor-specific transplan-
eff~~rKI>t;tm tolerance in vivo and in viu:o and excellent sur-
and resisted graft-versus-host disease. 
The model for fully xenogeneic chimeras was recently 
to examine whether rejection-free graft accep-
would occur for pancreatic islet xenografts. 15 Af-
the induction of diabetes in chimeras with strepto-
iOcin, donor-specific, or MHC-disparate third-party 
islet grafts were placed under the renal capsule. AI-
~ though third-party islet grafts were rapidly rejected 
~r (mean survival time, 9 days), donor-specific grafts were 
j;:;: permanently accepted and sufficient to maintain eugly-
when nonfasting blood glucose determinations 
performed. To examine whether true regulation of 
function and insulin production could occur in a 
xel[1o~~enKeic stromal environment, IPGTTs were per-
in selected recipients, with grafts surviving for 
than 8 months. In all animals examined, the K 
value and peak and basal insulin levels were compara-
. ~le to those for normal unmanipulated Bl0 mice in re-
. to a glucose challenge. 
. Stimulated insulin release (peak insulin level) was 
... slightly higher in the chimeras than in the normal mice, 
.but this difference was not significant. This finding 
. could be the result of the heterotopic site for implanta-
tion, resulting in endocrine drainage into the systemic 
circulation rather than the anatomic portal system. The 
higher stimulated insulin release in mice that received 
rat islet xenografts could also represent the high volume 
of transplanted islets (800), because it is well known that 
up to 600 rat or human islets are sufficient to induce 
normoglycemia in diabetic nude mice. 
_ The islet isolation procedure results in harvest of a 
complex containing acinar tissue, the glucagon-produc-
ing a-cells, insulin-producing ~-cellsI a-cells, lympho-
cytes, and antigen-presenting cells. To confirm the 
presence of expected a-cells, immunohistochemical anal-
ysis for glucagon was performed. As we previously 
identified for ~-cellsI the a-cells were healthy, had ev-
idence of the presence of glucagon, and had no evidence 
for chronic rejection even 8 months after transplantation 
into the xenogeneic chimeras. Interestingly, glucagon 
staining was significantly greater than that observed in 
the native pancreas of unmanipulated rats of the same 
donor strain. The overexpression of gl ucagon in trans-
planted islets has been observed by others in human, 
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rodent, and canine allograft models. 25 The mechanism 
for this effect is not understood but may represent a 
regulatory effect because the glucagon produced by the 
a-cells has a known counterregulatory role in glucose 
homeostasis. If the glycemic state were more variable 
after islet transplantation, with fluctuation in insulin 
production and therefore plasma glucose level, one 
might predict a-cell hypertrophy. 
In conclusion, the preparation of fully xenogeneic 
chimeras resulted in the induction of MHC-specific do-
nor-specific transplantation tolerance to pancreatic islet 
xenografts. Donor-specific islet xenografts exhibited 
rejection-free graft survival for 8 months or longer after 
transplantation. Most important, the grafts were func-
tional to maintain glucose homeostasis to a glucose 
challenge. Basal and peak insulin levels in chimeras 
were comparable to those of normal mouse controls. 
Taken together, these data demonstrate that pancreatic 
islet xenografts are regulated in function in a xenogeneic 
stromal environment. 
We thank Richard James and Cathie Carr for technical 
support and Drs. Sherry M. Wren, Christina Kaufman, and 
Ashraf Y. Abou El-Ezz for manuscript review. 
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DISCUSSION 
Dr. John B. Hanks (Charlottesville, Va.). Would you ex-
pect any changes if you put these in, say, the portal circula-
tion? There is some literature about hyperinsulinemia in sys-
temically drained grafts and perhaps some associated subtle 
changes in glucose metabolism. Have you used your model to 
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study the success of engraftment or to get at some of The 
changes that suggest some of the hyperinsulinemia as a result 
of the glucose challenge? 
Dr. lldstad. We have not looked at whether transplant,,: n 
of islets into the portal system can result in a lower in""lln 
level. We were more interested in using the present model for 
achieving permanent graft acceptance and tolerance induction, 
but now with the observation that there seems to be a differ-
ence in insulin levels, it would be interesting to explore and 
compare the effects. 
Dr. M. Wayne Flye (St. Louis, Mo.). This is an extension 
of work that you have been presenting with a bone marrow 
chimerism. You are using the B 1 0 mouse. Does this extrap-
olate to other stains of mice and rats? Have you looked at other 
xenoislets as well? That is going to be an important barrier 
to determine what is occurring. 
Dr.lldstad. We have looked at a number of different mOlIse 
and rat strain combinations, and this tolerance is a univ,.' d 
property. We have used BlOBR, BIO, and non obese dI:, :c 
as mouse recipients. The reason most of our data are war •. ;\e 
B 1 0 mouse strain is that we can get those animals more readdy 
than the other strains. We have used a number of different 
strain combinations for the rat donors as well, including AeI, 
Fisher 344, and Wistar-Furth. 
Dr. Flye. Can you cause these grafts to reject with either 
antibody or cells that are injected that have been sensitized' 
Dr. Ildstad. We can reverse chimerism if we give a very 
large number of naive recipient-type CD-4-positive spleno-
cytes, but we have not performed those studies in animals that 
have received islet xenografts, Only if we give one spleen 
equivalent, 30 million naive B 1 0 splenocytes, can we eliminate 
the chimerism and tolerance, but it takes a very large number 
of cells. 
Dr. K. L. Brayman (Minneapolis, Minn.). The mou 
a rather permissive recipient species for islet transplants. ",;d 
there are many manipulations that one can do in a mouse [Q 
get prolonged allogeneic and xenogeneic islet graft survival. Is 
this technique applicable in other recipient species such as rats 
or hamsters or guinea pigs or perhaps even in larger animals 
such as dogs or pigs. Do you have any experience with whether 
the xenogeneic chimeras and donor-specific islet transplanta-
tion will be applicable in higher species? 
Dr. lldstad. We have successfully performed transplanta-
tion of mouse bone marrow into rat recipients and also ham-
sters to mouse. Those chimeric animals exhibit tolerance in 
vitro. We have not yet performed islet grafts in them. We have 
not attempted to achieve xenogeneic chimerism in larger spe-
cies yet, However, there are a few groups that have done ;'::\-
boon into monkey and monkey into baboon successfull \ 
well as pig into pig. As with the rat/mouse combination. tL·e 
are closely related species that do not have preformed CytotoXIC 
antibody. 
K~ 
